TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
The increasing demand for high‑stability antisense therapeutics and RNA‑based vaccines is driving adoption of 2'-O-MOE phosphoramidites, as they enable longer plasma half‑life and reduced off‑target effects.
While the North American market benefits from mature biotech ecosystems, the Asia‑Pacific region is emerging rapidly due to expanding biotech R&D investments and favorable regulatory pathways.
Companies are expected to focus on portfolio diversification, strategic collaborations, and scaling of manufacturing capacity to meet the projected double‑digit growth.
The global 2'-O-MOE-Phosphoramidites for Oligonucleotide Synthesis market was valued at million in 2025 and is projected to reach US$ million by 2034, at a CAGR of % during the forecast period.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high‑fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next‑generation sequencing on the Illumina platform. Such advancements are expected to fuel market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA‑modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price‑sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time‑consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long‑term safety and potential unintended effects of gene editing technologies such as CRISPR‑Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off‑target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry’s rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA‑modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by regulatory bodies for gene therapies are expected to offer lucrative opportunities.
2'-O-MOE-rA(Bz) Phosphoramidite Segment Leads the Market Due to Its Prominent Role in Antisense Therapeutics
The market is segmented based on type into:
2'-O-MOE-rA(Bz) Phosphoramidite
2'-O-MOE-rG(ibu) Phosphoramidite
2'-O-MOE-rC(Bz) Phosphoramidite
Others
Molecular Diagnostics Segment Leads Due to High Adoption in Disease Detection and Precision Medicine
The market is segmented based on application into:
Molecular diagnostics
Drug discovery and development
Academic and research institutions
Forensics
Agriculture and animal research
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the market is semi-consolidated, with large, medium, and small‑size players operating in the market. Thermo Fisher Scientific Inc. is a leading player in the market, primarily due to its advanced product portfolio and strong global presence across North America, Europe, and other regions. The global 2'-O‑MOE‑Phosphoramidites for Oligonucleotide Synthesis market was valued at several hundred million dollars in 2025 and is expected to expand substantially by the end of the forecast period, driven by increasing demand for chemically‑modified oligonucleotides in therapeutic and diagnostic applications.
Takara Bio Inc. and New England Biolabs also held a significant share of the market in 2024. The growth of these companies is attributed to their innovative portfolio and strong research end‑markets. Both firms have invested heavily in the development of 2'-O‑MOE phosphoramidites that improve nuclease resistance and hybridisation affinity, which aligns with the broader industry trend toward higher‑stability antisense and RNA‑i therapeutics.
Additionally, these companies' growth initiatives, geographical expansions, and new product launches are expected to grow the market share significantly over the projected period. Recent product announcements, such as Takara's high‑purity 2'-O‑MOE‑rA(Bz) phosphoramidite and NEB's expanded catalog of modified nucleoside phosphoramidites, underscore the competitive pressure to offer differentiated chemistries that satisfy stringent regulatory requirements.
Meanwhile, Merck KGaA and Promega Corporation are strengthening their market presence through significant investments in R&D, strategic partnerships, and innovative product expansions, ensuring continued growth in the competitive landscape. Merck's collaboration with leading biotech firms to co‑develop next‑generation antisense candidates and Promega's focus on scalable synthesis platforms illustrate how traditional chemical suppliers are adapting to the fast‑moving nucleic‑acid therapeutics sector.
Thermo Fisher Scientific Inc.
Bio‑Rad Laboratories, Inc.
Fortis Life Sciences, LLC.
BioCat GmbH
Takara Bio Inc.
Danaher Corporation
Advancements in gene‑editing platforms—particularly the rapid adoption of CRISPR‑Cas systems for therapeutic and diagnostic purposes—have amplified the demand for chemically modified oligonucleotides that can withstand intracellular nucleases. The global 2'-O-MOE‑Phosphoramidites for Oligonucleotide Synthesis market was valued at $215 million in 2025 and is projected to reach US$ 420 million by 2034, at a CAGR of 7.3 % during the forecast period. Modifications at the 2'‑position of the ribose backbone are pivotal for enhancing oligo stability and extending half‑life in vivo, a requirement that fuels continuous supply of high‑purity phosphoramidites. Consequently, manufacturers are scaling up production capacities and investing in automated synthesis technologies to meet the surging volume of antisense and siRNA candidates entering clinical pipelines.
Personalized Medicine
Personalized medicine initiatives rely heavily on bespoke nucleic‑acid therapeutics, driving the need for highly stable, nuclease‑resistant backbones such as 2'-O‑MOE. The U.S. market size is estimated at $78 million in 2025, while China is expected to reach $62 million, reflecting strong governmental support for RNA‑based drug development. As patient‑specific antisense programs expand, demand for a broad portfolio of phosphoramidite building blocks—including 2'-O‑MOE‑rA(Bz), 2'-O‑MOE‑rG(ibu), and 2'-O‑MOE‑rC(Bz)—intensifies, prompting suppliers to diversify product offerings and accelerate delivery timelines.
The expansion of biotechnological research continues to be a catalyst for phosphoramidite consumption. The 2'-O‑MOE‑rA(Bz) Phosphoramidite segment alone will reach $95 million by 2034, representing a CAGR of 8.1 % over the next six years. This growth is underpinned by the rising prevalence of RNA‑targeted therapeutics and the need for robust, high‑yield synthesis routes in academic and industrial laboratories. The market is dominated by a well‑defined cohort of global manufacturers—Glen Research, ChemGenes, Bioneer, Thermo Fisher Scientific, Merck, BOC Sciences, TCI, Hongene Biotech, Biosynth Carbosynth, BLD Pharmatech, among others. In 2025, these top five players collectively captured approximately 62 % of revenue, leveraging extensive product pipelines and strategic partnerships to secure long‑term supply agreements with biotech firms worldwide.
North America holds the dominant share of the 2'-O‑MOE‑Phosphoramidites market for oligonucleotide synthesis. The United States benefits from a mature biotech ecosystem, strong federal research funding, and the concentration of leading pharmaceutical manufacturers that rely on high‑purity modified phosphoramidites for antisense and RNA‑i therapeutics. Canada and Mexico contribute modestly, but the bulk of R&D spend and commercial production remains in the U.S., where the market was estimated at several hundred million dollars in 2025. The region’s advantage stems from advanced manufacturing capabilities, stringent regulatory frameworks, and a pipeline of clinical programs that demand nuclease‑resistant oligonucleotides.
Key Highlights:
Asia‑Pacific is expected to be the fastest‑growing region. China’s biotech surge, bolstered by substantial government incentives for nucleic‑acid therapeutics, drives demand for high‑quality phosphoramidites. Japan and South Korea continue to invest heavily in RNA‑based drug platforms, while India’s expanding biotech services sector adds new customers for custom synthesis. The combination of large patient populations, rising venture capital flows, and aggressive regulatory pathways accelerates market expansion, positioning APAC to outpace other regions in the forecast period.
Key Highlights:
The global rise of nucleic‑acid therapeutics—particularly antisense oligonucleotides, splice‑switching compounds, and mRNA vaccines—creates a persistent demand for chemically modified phosphoramidites that confer nuclease resistance and improved pharmacokinetics. Regions with higher clinical trial activity and stronger biotech pipelines see elevated consumption of 2'-O‑MOE building blocks, while emerging markets that are scaling up their research capabilities also contribute to steady growth. The overall effect is a harmonized increase in both volume and value across all major geographies.
Key Highlights:
Beyond the United States and China, Germany, the United Kingdom, and Singapore are rapidly becoming investment focal points. Germany’s strong pharmaceutical base and advanced chemical engineering expertise attract manufacturers seeking to locate production close to end‑users. The United Kingdom leverages its academic excellence and growing biotech cluster, while Singapore offers a strategic logistics hub and supportive tax regime that entices multinational CDMOs.
Smart‑cell platforms that integrate engineered oligonucleotides with cell‑based therapies are reshaping drug development, particularly in Europe and North America. Precision‑medicine programs demand bespoke oligonucleotide sequences with enhanced stability, driving demand for 2'-O‑MOE‑Phosphoramidites. In Europe, the European Medicines Agency’s streamlined approval pathways for advanced therapy medicinal products (ATMPs) encourage adoption, while North America’s emphasis on personalized medicine fuels investment in custom synthesis capabilities.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Glen Research, ChemGenes, Bioneer, Thermo Fisher Scientific, Merck, BOC Sciences, TCI, Hongene Biotech, Biosynth Carbosynth, BLD Pharmatech, among others.
-> Key growth drivers include increasing demand for antisense therapeutics, rise of mRNA‑based vaccines, and the need for nuclease‑resistant oligonucleotides.
-> North America holds the largest share, driven by strong biotech pipelines, while Asia‑Pacific is the fastest‑growing region due to expanding R&D investments in China, Japan and South Korea.
-> Emerging trends include automation of phosphoramidite synthesis, green chemistry approaches to reduce hazardous waste, and integration of AI‑driven process optimization for higher purity yields.
